Asia's New Hub for Antibody & ADC Innovation
Advance Discovery. Streamline Development. Accelerate Commercialization.
Future-Proofing Innovation from Day One
Step into 2 days of breakthrough science, strategic connections, and game-changing opportunities. The Antibody & ADC Summit at ChinaBio® brings together Asia's most dynamic antibody and ADC innovation ecosystem in Shanghai.
✔ Insights from global pioneers in antibody engineering, bispecifics, and ADCs
Dedicated presentations spanning antibody therapeutics and ADC discovery to clinic
✔ Strategic 1:1 meetings through partneringONE® to turn conversations into partnerships
Fireside conversations exploring CDMO-partner collaborations that evolved beyond transactional relationships
Antibody ADC Summit at ChinaBio
Senior leadership executives and decision-makers responsible for bioprocessing strategy, manufacturing partnerships, and commercialization planning in small to mid-size biotech, large pharma, CDMO, and related biopharmaceutical companies.
C-level Leadership:
- Founder
- Chief Executive Officer (CEO)
- Chief Operating Officer (COO)
- Chief Manufacturing Officer (CMO)
- Chief Technical Officer (CTO)
- Chief Quality Officer (CQO)
- Chief Strategy Officer (CSO)
Senior Vice Presidents and Vice Presidents of:
- Manufacturing & Operations
- Technical Operations
- Process Development
- Quality & Compliance
- Supply Chain Logistics
- Strategic Partnerships
Global Directors / Heads of:
- Bioprocessing & Biomanufacturing
- Manufacturing Strategy
- Technology Transfer
- Facility Planning & Design
- CDMO Partnerships
- Manufacturing Innovation
Let’s Talk Science
We’re Diving Into the Details with two focused tracks covering everything from antibody engineering and bispecific design to ADC payloads, linker chemistry, and clinical updates.
Antibody Engineering & Antibody Therapeutics
- Bispecific and Multispecific Antibodies
- Novel Techniques for Antibody Engineering
- Dual-specific Antibodies
- Gated Antibodies
- Novel Engineering Strategies to Avoid Toxicity of T-cell Engagers
- Antibodies for Novel Targets
- Applications of AI and ML in Antibody Development & Drug Discovery
- Multi-objective Lead Optimization Using AI/ML
- De Novo Hit Discovery Using AI and ML
- Preclinical and Clinical Updates on PD1/PDL1/VEGF Bispecifics
- Antibodies for Autoimmune Diseases
- Antibodies for Immunity and Inflammation
Antibody-Drug Conjugates
- Novel ADC Payloads
- Tumor-specific Release of Payloads
- Multi-payloads for ADCs
- Mechanisms of how ADCs work: Internalization, ADC tumor killing, Antigen Expression Levels and Interactions
- Linker chemistry strategy (biology and chemistry)
- Conditional Antibody Binding
- Pharmacology and Mechanisms of ADCs: Metabolic Rate, Tumor Penetration
- ADC Clinical Updates
- Innovations in ADC Manufacturing
China’s Biotech Boom: Unlocking Antibody & ADC Potential
China’s antibody and ADC field is accelerating with record investment, expanding pipelines, and breakthrough approvals. From discovery to late-stage programs, the region is fast becoming a global growth engine with new opportunities for collaboration and market entry.
Where Science Meets Market Opportunity
The buzz isn’t just hype. Investment in antibodies and ADCs is exploding in China. Add in the fact that we’re co‑located with ChinaBio® Partnering Forum and the Cell & Gene Therapy Summit, and suddenly you’re rubbing shoulders with 1,000+ scientists, execs, and investors!
Next-Gen Therapies in Development
China’s not slowing down. Hundreds of antibody and ADC clinical programs are already in motion across oncology, immunology, and rare disease. Translation? More chances to plug into pipelines, collabs, and partnerships that actually move the needle.
Program Spotlight
Two focused tracks - Antibody Engineering & Therapeutics and Antibody-Drug Conjugates which cover everything from bispecifics, gated antibodies, and AI/ML in discovery, to payload design, linker chemistry, and cutting-edge clinical updates.
The earlier you register, the more you save
Learn about the next era of Cell & Gene Therapy in China